The Christ Hospital

AskBio's AB-1002 Gene Therapy Shows Promise in Heart Failure

4 months ago

• AskBio's AB-1002 gene therapy demonstrates preliminary efficacy in treating congestive heart failure, with no serious adverse events reported in early clinical data. • The Phase 1 study (NAN-CS101) showed clinically meaningful improvements in left ventricular ejection fraction (LVEF) in a subset of patients with NYHA Class III heart failure. • AB-1002 delivers a gene coding for inhibitor-1 (I-1), which blocks protein phosphatase 1 (PP1), a target implicated in the development of heart failure. • Bayer's AskBio is planning a Phase 2 trial to further evaluate the safety and efficacy of AB-1002 in a larger patient population.

Christ Hospital Surgeons Implant Bivacor Total Artificial Heart as Bridge to Transplant

6 months ago

• Surgeons at The Christ Hospital successfully implanted the Bivacor Total Artificial Heart in a patient awaiting a heart transplant, marking the fourth such procedure worldwide. • The Bivacor device serves as a temporary replacement for the complete function of the heart, acting as a bridge until a donor heart becomes available. • The artificial heart is currently undergoing early-stage FDA approval and is part of a clinical study to assess its potential to revolutionize heart transplantation. • The recipient, Mike Herrman, experienced significant improvement while using the device for 15 days, highlighting its potential to enhance the quality of life for patients with severe heart conditions.

Shockwave Javelin IVL Catheter Demonstrates High Success Rate in PAD Treatment

7 months ago

• The Shockwave Javelin Peripheral IVL Catheter achieved a 99% technical acute procedural success rate in treating peripheral artery disease (PAD). • The catheter is designed to modify calcium and cross extremely narrowed vessels in PAD patients, offering a new approach to IVL application. • Clinical trial results supported FDA clearance of the Shockwave Javelin technology, providing an effective alternative for difficult-to-cross lesions. • Johnson & Johnson MedTech's acquisition of Shockwave Medical expands its cardiovascular research leadership and innovation in PAD treatment.